---
title: "Zevra Therapeutics, Inc. (ZVRA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ZVRA.US.md"
symbol: "ZVRA.US"
name: "Zevra Therapeutics, Inc."
industry: "Pharmaceuticals"
---

# Zevra Therapeutics, Inc. (ZVRA.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [zevra.com](https://zevra.com) |

## Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is unde...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: B (0.30)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 29 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 244.60% |  |
| Net Profit YoY | 133.48% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.76 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 500.49M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 84.39M |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 29.58% | A |
| Profit Margin | 41.86% | A |
| Gross Margin | 95.25% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 244.60% | A |
| Net Profit YoY | 133.48% | A |
| Total Assets YoY | 41.02% | A |
| Net Assets YoY | 90.86% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 281.14% | C |
| OCF YoY | 244.60% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.37 | C |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 50.70% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Zevra Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "29.58%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "41.86%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "95.25%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "244.60%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "133.48%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "41.02%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "90.86%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "281.14%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "244.60%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "50.70%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 16.67 | 21/257 | 16.92 | 16.21 | 15.74 |
| PB | 3.76 | 124/257 | 11.54 | 5.27 | 3.75 |
| PS (TTM) | 5.93 | 101/257 | 16.19 | 9.97 | 5.96 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-11T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 75% |
| Overweight | 2 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.80 |
| Highest Target | 26.00 |
| Lowest Target | 18.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ZVRA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ZVRA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ZVRA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.